Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marius M Hoeper

Showing results (51-60 of 311) with videos related to

Pageof 32
Sort By:
The European Respiratory Journal|March 30, 2019
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionMarc Humbert, Harrison W Farber, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 1, 2012
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trialMarius M Hoeper, Michael Halank, Heinrike Wilkens, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 1, 2015
Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatmentAnn-Kathrin Strunk, Sandra Ciesek, Julius J Schmidt, et al.
Chest|October 16, 2010
Osteopontin in patients with idiopathic pulmonary hypertensionJohan M Lorenzen, Nils Nickel, Robert Krämer, et al.
Respiratory Medicine|November 26, 2016
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?Steven D Nathan, Jürgen Behr, Vincent Cottin, et al.
Journal of the American College of Cardiology|June 15, 2004
End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectivesMarius M Hoeper, Ronald J Oudiz, Andrew Peacock, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 30, 2005
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertensionJan T Kielstein, Stefanie M Bode-Böger, Gerrit Hesse, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|September 14, 2018
Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk scoreAdaani E Frost, Marius M Hoeper, Joan Albert Barberá, et al.
BMC Health Services Research|June 11, 2014
Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countriesBernd Schweikert, David Pittrow, Carmine Dario Vizza, et al.
BMC Nephrology|April 15, 2011
Effect of acute kidney injury requiring extended dialysis on 28 day and 1 year survival of patients undergoing interventional lung assist membrane ventilator treatmentJan T Kielstein, Soeren Tolk, Carsten Hafer, et al.
Pageof 32

Showing results (51-60 of 311) with videos related to

Sort By:
Pageof 32
The European Respiratory Journal|March 30, 2019
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionMarc Humbert, Harrison W Farber, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 1, 2012
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trialMarius M Hoeper, Michael Halank, Heinrike Wilkens, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 1, 2015
Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatmentAnn-Kathrin Strunk, Sandra Ciesek, Julius J Schmidt, et al.
Chest|October 16, 2010
Osteopontin in patients with idiopathic pulmonary hypertensionJohan M Lorenzen, Nils Nickel, Robert Krämer, et al.
Respiratory Medicine|November 26, 2016
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?Steven D Nathan, Jürgen Behr, Vincent Cottin, et al.
Journal of the American College of Cardiology|June 15, 2004
End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectivesMarius M Hoeper, Ronald J Oudiz, Andrew Peacock, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 30, 2005
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertensionJan T Kielstein, Stefanie M Bode-Böger, Gerrit Hesse, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|September 14, 2018
Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk scoreAdaani E Frost, Marius M Hoeper, Joan Albert Barberá, et al.
BMC Health Services Research|June 11, 2014
Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countriesBernd Schweikert, David Pittrow, Carmine Dario Vizza, et al.
BMC Nephrology|April 15, 2011
Effect of acute kidney injury requiring extended dialysis on 28 day and 1 year survival of patients undergoing interventional lung assist membrane ventilator treatmentJan T Kielstein, Soeren Tolk, Carsten Hafer, et al.
Pageof 32